According to a recent study, almost one-fourth of dialysis patients undergoing PCI receive an antithrombotic agent (enoxaparin or eptifibatide) that is contraindicated in individuals with renal disease, resulting in excessive major bleeding and death.
In a CardioExchange blog, the study’s lead author notes that this error was more likely to occur in hospitals that were rural or non-teaching or that had lower procedural volumes. He recommends (a) using EMR to avoid this and (b) providing safety seminars in residency/fellowship training programs.
Will such strategies be effective in the hospital settings where this error is most likely to occur?